HHS Awards $13M for Influenza Vaccine Research to Advanced Technology International
Contract Overview
Contract Amount: $13,000,000 ($13.0M)
Contractor: Advanced Technology International
Awarding Agency: Department of Health and Human Services
Start Date: 2024-06-07
End Date: 2031-09-30
Contract Duration: 2,671 days
Daily Burn Rate: $4.9K/day
Competition Type: FULL AND OPEN COMPETITION
Pricing Type: FIRM FIXED PRICE
Sector: R&D
Official Description: OT TASK ORDER 7-CENTRAL INFLUENZA AND EMERGING INFECTIOUS DISEASES VACCINE IMMUNOGENICITY LABORATORY SERVICES
Place of Performance
Location: SUMMERVILLE, BERKELEY County, SOUTH CAROLINA, 29486
Plain-Language Summary
Department of Health and Human Services obligated $13.0 million to ADVANCED TECHNOLOGY INTERNATIONAL for work described as: OT TASK ORDER 7-CENTRAL INFLUENZA AND EMERGING INFECTIOUS DISEASES VACCINE IMMUNOGENICITY LABORATORY SERVICES Key points: 1. This contract focuses on critical R&D in biotechnology, specifically vaccine immunogenicity. 2. The awardee, Advanced Technology International, is a known entity in this sector. 3. The long duration (2031) suggests a sustained need for these services. 4. The fixed-price contract type aims to control costs for the government.
Value Assessment
Rating: good
The $13 million award over approximately 7.5 years appears reasonable for specialized R&D services in vaccine development. Benchmarking against similar long-term biotechnology research contracts would provide further context.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, suggesting a robust price discovery process. This method typically leads to more competitive pricing.
Taxpayer Impact: Full and open competition generally benefits taxpayers by ensuring the government receives the best value through a competitive bidding process.
Public Impact
Enhances national preparedness for influenza and emerging infectious diseases. Supports the development of more effective vaccines. Contributes to public health security through advanced research.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Long contract duration may require ongoing performance monitoring.
- Potential for scope creep in R&D projects.
Positive Signals
- Awarded via full and open competition.
- Firm fixed-price contract type.
- Focus on critical public health research.
Sector Analysis
This contract falls under Research and Development in Biotechnology, a sector vital for public health and national security. Spending in this area is often driven by evolving threats and the need for innovation.
Small Business Impact
The data does not indicate if small businesses were involved in this specific task order. Further analysis would be needed to determine small business participation.
Oversight & Accountability
The Office of Assistant Secretary for Preparedness and Response (ASPR) is responsible for this award, indicating a focus on preparedness and response capabilities. Oversight will be crucial for ensuring research milestones are met.
Related Government Programs
- Research and Development in Biotechnology (except Nanobiotechnology)
- Department of Health and Human Services Contracting
- Office of Assistant Secretary for Preparedness and Response Programs
Risk Flags
- Long-term contract duration
- R&D project inherent uncertainties
- Potential for evolving scientific landscape
Tags
research-and-development-in-biotechnolog, department-of-health-and-human-services, sc, delivery-order, 10m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $13.0 million to ADVANCED TECHNOLOGY INTERNATIONAL. OT TASK ORDER 7-CENTRAL INFLUENZA AND EMERGING INFECTIOUS DISEASES VACCINE IMMUNOGENICITY LABORATORY SERVICES
Who is the contractor on this award?
The obligated recipient is ADVANCED TECHNOLOGY INTERNATIONAL.
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).
What is the total obligated amount?
The obligated amount is $13.0 million.
What is the period of performance?
Start: 2024-06-07. End: 2031-09-30.
What specific immunogenicity metrics will be used to evaluate vaccine effectiveness under this contract?
The contract likely specifies detailed immunogenicity assays and endpoints, such as antibody titers, neutralization capacity, and cellular immune responses. These metrics are crucial for assessing a vaccine's ability to elicit a protective immune response against target pathogens like influenza and emerging infectious diseases.
What are the primary risks associated with the long-term nature of this R&D contract?
Key risks include potential shifts in scientific priorities, the emergence of superior alternative technologies, and challenges in maintaining consistent research quality over an extended period. Unforeseen scientific hurdles or changes in the threat landscape could also impact the project's relevance and success.
How will the effectiveness of the awarded research be measured and translated into public health benefits?
Effectiveness will likely be measured through rigorous scientific review of research outcomes, milestone achievement, and the successful development of candidate vaccines or immunogenicity data. Translation into public health benefits depends on subsequent clinical trials, regulatory approval, and eventual deployment of improved vaccines.
Industry Classification
NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)
Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: 315 SIGMA DR, SUMMERVILLE, SC, 29486
Business Categories: Category Business, Corporate Entity Tax Exempt, Nonprofit Organization, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $13,000,000
Exercised Options: $13,000,000
Current Obligation: $13,000,000
Actual Outlays: $7,455
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED
Cost or Pricing Data: NO
Parent Contract
Parent Award PIID: 75A50123D00005
IDV Type: IDC
Timeline
Start Date: 2024-06-07
Current End Date: 2031-09-30
Potential End Date: 2031-09-30 00:00:00
Last Modified: 2026-01-27
More Contracts from Advanced Technology International
- OT Task Order 4 — $1.0B (Department of Health and Human Services)
- OTA Task Order 1 — $795.0M (Department of Health and Human Services)
- OT Task Order 3 — $723.5M (Department of Health and Human Services)
- OT Task Order 8-Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability — $418.7M (Department of Health and Human Services)
- Other Transaction: Production of Drug Substances and Drug Products AT Commercial Scale Under Biomap-Consortium — $304.0M (Department of Health and Human Services)
View all Advanced Technology International federal contracts →
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →